|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||101.00 - 101.00|
|52 Week Range||67.00 - 108.50|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||76.17|
|Forward Dividend & Yield||1.47 (1.46%)|
|Ex-Dividend Date||Sep 29, 2021|
|1y Target Est||N/A|
Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).
View more earnings on CDXSSee more from BenzingaClick here for options trades from BenzingaBioNTech Starts Dosing In Mid-Stage Melanoma Vaccine TrialBristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over B For Rights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody-drug conjugate (ADC). Bristol Myers will pay $650 million, including $200 million to Eisai's R&D efforts, for shared global rights to MORAb-202, the Japanese company's first ADC, which is a combination between an in-house folate receptor antibody and chemotherapy eribulin, marketed as Ha